Breaking Finance News

Barclays Capital covered Tesaro Inc (NDAQ:TSRO), stepping up its target to $135.00 earlier today

Barclays Capital bumped up the target of Tesaro Inc (NDAQ:TSRO) to $135.00 stating a potential upside of 0.18%.

On 10/12/2017, H.C. Wainwright released a statement for Tesaro Inc (NDAQ:TSRO) bumped up the target price from $0.00 to $158.00 that suggested an upside of 0.32%.

Boasting a price of $114.01, Tesaro Inc (NDAQ:TSRO) traded -1.64% lower on the day. With the last stock price close down -13.78% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Tesaro Inc has recorded a 50-day average of $120.86 and a two hundred day average of $132.79. Volume of trade was down over the average, with 223,726 shares of TSRO changing hands under the typical 835,155

Performance Chart

Tesaro Inc (NDAQ:TSRO)

With a total market value of $0, Tesaro Inc has with a one year low of $106.64 and a one year high of $192.94 .

A total of 10 equity analysts have released a ratings update on TSRO. Eight equity analysts rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $89.00.

Brief Synopsis About Tesaro Inc (NDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.